Navigation

Costing tools

Costing tools are normally provided for each technology appraisal, quality standard, medical technology, diagnostic technology, clinical guideline and public health guidance. Costing tools are not provided for interventional procedures.

Types of costing tool

NICE provides five types of costing tool:

  • national cost reports summarise the national estimate cost and discuss the assumptions made when estimating the financial impact of implementing the guidance. For technology appraisals, the report is incorporated into the costing template.
  • costing templates support estimating the local cost of implementing guidance. and public health guidelines. These templates allow individual NHS organisations and local health economies to quickly assess the impact guidance will have on local budgets. A video tutorial explaining how to use the costing templates is available in Windows Media Player and Quick Time format.
  • business case. It presents the financial costs and benefits of implementing guidance.
  • cost impact and commissioning assessment for NICE quality standards
  • costing statements are used when cost impact is considered to be minimal to explain why the cost impact is not considered to be significant.
  • NICE support for commissioners and others using the quality standard

All guidance published since January 2005 has costing tools. Costing tools currently available are listed below.

Further information on the methodology for developing costing tools.

Results 21-40 of 511

Ref Title
TA289 Myelofibrosis (splenomegaly, symptoms) - ruxolitinib: costing statement
TA288 Type 2 diabetes - Dapagliflozin combination therapy: costing template
TA287 Pulmonary embolism and recurrent venous thromboembolism - rivaroxaban: costing template
TA285 Ovarian, fallopian tube and primary peritoneal cancer (recurrent advanced, platinum-sensitive or partially platinum-sensitive) - bevacizumab: costing statement
TA284 Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer: costing statement
TA283 Macular oedema (retinal vein occlusion) - ranibizumab: costing template
TA282 Idiopathic pulmonary fibrosis - pirfenidone: costing template
TA280 Rheumatoid arthritis - abatacept (2nd line) (rapid review of TA234): costing statement
TA279 Vertebral fractures - vertebroplasty and kyphoplasty: costing statement
TA278 Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201): costing statement
TA276 Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin: costing statement
TA275 Stroke and systemic embolism (prevention, non-valvular atrial fibrillation) - apixaban: costing statement
TA274 Macular oedema (diabetic) - ranibizumab: costing template
TA272 Urothelial tract carcinoma (transitional cell, advanced, metastatic) - vinflunine: costing statement
TA271 Diabetic macular oedema - fluocinolone acetonide intravitreal implant: costing statement
TA269 Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: costing template
TA268 Melanoma (stage III or IV) - ipilimumab: costing statement
TA267 Chronic heart failure - ivabradine: costing template
TA266 Cystic fibrosis - mannitol dry powder for inhalation: costing statement
TA265 Bone metastases from solid tumours - denosumab: costing template

This page was last updated: 31 August 2011

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.